APOTEX CORP. for APOTEX CORP.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Manufacturing MAN
Executive Order No. 14017, America's Supply Chains (February 24, 2021), provisions relating to strengthening domestic manufacturing of active pharmaceutical ingredients and finished dosages
Foreign entity interest: Aposherm Delaware Holdings Corporation, Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Health Issues HCR
HR 5376, the Build Back Better Act, Sections 139001, 139101, 131902 provisions relating to negotiating Medicare prescription drug prices, Medicare Part B pharmaceutical rebates, and Medicare Part D rebates respectively; HR 2853, the BLOCKING Act, provisions relating to amending the Hatch-Waxman Act 180-day exclusivity structure; S2910, Expanding Access to Low Cost Generics Act, provisions relating to amending the Hatch-Waxman Act's 180-day exclusivity structure; S2740, the Promoting Readiness and Ensuring Proper Active pharmaceutical ingredient Reserves of Essential Medicines Act of 2021, provisions relating to establishing a strategic national stockpile of active pharmaceutical ingredients for essential medicines; and HR 2870, the Essential Medicines Strategic Stockpile Act of 2021, provisions relating to creating a pilot program with private entities to test the effectiveness of acquiring, maintaining, managing, and distributing a stockpile of generic drugs at risk of shortage.
Foreign entity interest: Aposherm Delaware Holdings Corporation, Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.